News & Events

• December 2, 2019
  

  Workshop Summary, Advancing the Development and Implementation of Analysis Data Standards, Now Available

  C-Path is proud to announce the availability of the workshop summary, Advancing the Development and Implementation of Analysis Data Standards: Key Challenges and Opportunities. The workshop, in collaboration with the Duke-Margolis Center for Health Policy and the Food and Drug Administration (FDA), was planned with the support of C-Path data standard expertise, and included a...
• October 29, 2019
  

  U.S. Senator Martha McSally Visits C-Path

  U.S. Senator Martha McSally (Arizona) visited Tucson-based Critical Path Institute (C-Path) Friday, October 25, to learn more about its mission to accelerate drug development. C-Path, founded in 2005, aims to catalyze the development of new approaches that advance medical innovation and regulatory science through collaboration and public and private partnerships. “C-Path is a unique leader...
• October 15, 2019
  

  C-Path, CDISC Develop Standard to Represent Data for Animal Rule Studies

  C-Path and CDISC are pleased to announce the release of a global Foundational Standard that describes how to represent data for the natural history and efficacy studies conducted in animals submitted to applications under the U.S. Food and Drug Administration (FDA) regulations commonly known as the Animal Rule.

• September 30, 2019
  

  The Critical Path for Parkinson’s Consortium (CPP) welcomes PMD Alliance as newest member

  The Critical Path for Parkinson’s Consortium (CPP) is thrilled to welcome the PMD Alliance (Parkinson & Movement Disorder Alliance) as our newest member. The PMD Alliance is an independent, national nonprofit organization that provides opportunities for people impacted by Parkinson’s and other movement disorders to learn, live life more fully, and connect with others. Their...
• September 19, 2019
  

  Innovative Data and Analytics Platform to Accelerate Drug Development for Rare Diseases

  Launched by C-Path and NORD through an FDA grant, the goal of the new platform is to accelerate the development of cures by addressing the need to better characterize rare diseases.